Year
2023
-
US FDA approves Acadia Pharmaceuticals’ Rett syndrome therapy
-
Satellos Bioscience Announces Further Preclinical Progress with SAT-3153 as a Potential Treatment for Duchenne Muscular Dystrophy
-
Formology Lab Gets Warning Letter for Lax Identity Testing, Other Lapses
-
Positive phase 2 data from Atrial Fibrillation clinical trial – primary endpoint met
-
FDA Offers Advice on NDAs for Postoperative Local Anesthetics
-
Paxlovid Gets Advisory Panel Support for Full FDA Approval
-
Mayo Clinic cancer expert highlights advancements in treating multiple myeloma
-
Xtandi Shows Promise in Prostate Cancer Trial
-
FDA Green Lights Clinical Trial of Low-Dose Psilocybin
-
Fusion Pharmaceuticals Announces First Patient Dosed in Phase 1 Study of FPI-2059, a Targeted Alpha Therapy (TAT) for the Treatment of Solid Tumors Expressing NTSR1